Dr. Reddy's Laboratories has launched rivastigmine tartrate capsules, a treatment for dementia caused by Alzheimer's or Parkinson's disease, in the U.S. market.


Dr. Reddy's Laboratories, rivastigmine tartrate capsules, Exelon, generic, bioequivalent, Novartis, dementia, Alzheimer's, Parkinson's


































































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Supplier News Breaks Archives

Dr. Reddy's ships generic version of Exelon

September 22nd, 2011

HYDERABAD, India – Dr. Reddy's Laboratories has launched rivastigmine tartrate capsules, a treatment for dementia caused by Alzheimer's or Parkinson's disease, in the U.S. market.

The pharmaceutical company said Thursday that its rivastigmine tartrate capsules are available in strengths of 1.5 mg, 3 mg, 4.5 mg and 6 mg and come in 60-count bottles.

According to Dr. Reddy's, the Food and Drug Administration-approved product is a bioequivalent generic version of Novartis' Exelon capsules.

U.S. sales of Exelon brand and generic rivastigmine tartrate capsules totaled approximately $92.6 million for the 12 months ended June 2011, according to IMS Health data cited by Dr. Reddy's.

Advertisement